Nilo Therapeutics

Executive Summary

Nilo Therapeutics is a Boston-based preclinical biotech company pioneering small molecule therapies for historically undruggable oncology targets. Founded in 2020 and backed by $101M in funding, the company leverages a proprietary platform to identify precision oncology candidates aimed at high-unmet-need cancers. With a focus on novel mechanisms, Nilo's pipeline targets pathways that have eluded traditional drug development. The company's early-stage programs have potential for first-in-class or best-in-class positioning, though clinical validation is pending. Given its strong financial backing and innovative platform, Nilo is well-positioned to advance toward clinical stages, but execution risks remain high as it has not yet entered human trials.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Program65% success
• TBDPreclinical Data Presentation at Major Oncology Conference80% success
• H2 2026Potential Series C Financing or Strategic Partnership50% success